MYT1L Gene

Migration, Crosslink

📖

MYT1L Gene

active

wiki page Created: 2026-04-02T07:19:30 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-myt1l

📖 Wiki Page

gene3099 wordssynced 2026-04-02

MYT1L Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MYT1L — Myelin Transcription Factor 1-like</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>MYT1L</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Myelin Transcription Factor 1 Like</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>2p25.3</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/23040" target="_blank">23040</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116254" target="_blank">ENSG00000116254</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/613084" target="_blank">613084</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9UL36" target="_blank">Q9UL36</a></td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein coding</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Zinc finger transcription factor</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (neurons), spinal cord</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

MYT1L — Myelin Transcription Factor 1-like

Overview

...

MYT1L Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MYT1L — Myelin Transcription Factor 1-like</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>MYT1L</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Myelin Transcription Factor 1 Like</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>2p25.3</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/23040" target="_blank">23040</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116254" target="_blank">ENSG00000116254</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/613084" target="_blank">613084</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9UL36" target="_blank">Q9UL36</a></td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein coding</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Zinc finger transcription factor</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (neurons), spinal cord</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

MYT1L — Myelin Transcription Factor 1-like

Overview

MYT1L (Myelin Transcription Factor 1-like) is a zinc finger transcription factor that plays a critical role in neuronal development, differentiation, and maintenance. As one of the key transcription factors driving neuronal fate specification, MYT1L is essential for the conversion of neural progenitor cells into functional neurons and for maintaining neuronal identity throughout life [1](https://pubmed.ncbi.nlm.nih.gov/25644679/). The gene encodes a protein with multiple zinc finger domains that binds to specific DNA sequences to regulate the expression of genes critical for neuronal function.

The importance of MYT1L in neurobiology extends beyond development into the realm of neurodegenerative diseases. Research has shown that MYT1L expression is altered in Alzheimer's disease, Parkinson's disease, and several neurodevelopmental disorders [2](https://pubmed.ncbi.nlm.nih.gov/29507854/). This makes MYT1L not only a key player in normal brain function but also a gene of significant interest for understanding disease mechanisms and developing therapeutic interventions.

Gene Overview

| Property | Value |
|----------|-------|
| Official Symbol | MYT1L |
| Full Name | Myelin Transcription Factor 1 Like |
| Gene ID | 23040 |
| Chromosomal Location | 2p25.3 |
| Ensembl ID | ENSG00000116254 |
| UniProt ID | Q9UL36 |
| OMIM | 613084 |
| Gene Type | Protein coding |
| Protein Class | Zinc finger transcription factor (C2H2-type) |

Molecular Function

Protein Structure

MYT1L encodes a transcription factor characterized by:

Zinc Finger Domains: Multiple C2H2-type zinc finger motifs that mediate DNA binding. These domains coordinate zinc ions to form stable finger-like structures that insert into the major groove of DNA [3](https://pubmed.ncbi.nlm.nih.gov/27878467/).

Transcriptional Repressor Domain: Regions outside the zinc fingers that interact with chromatin-modifying enzymes and other transcriptional regulators.

Nuclear Localization Signal: Sequences that direct the protein to the nucleus where it functions.

DNA Binding Specificity

MYT1L recognizes specific DNA sequences through its zinc finger domains:

Binding Sites: Consensus sequences typically contain GC-rich elements
Target Genes: Genes involved in neuronal differentiation, synaptic function, and cell survival
Regulation: Can both activate and repress gene transcription depending on context

Transcriptional Regulation

MYT1L functions as both a transcriptional activator and repressor:

Activation Functions:

Activates neuron-specific gene expression
Promotes expression of synaptic proteins
Induces genes involved in neurotransmitter synthesis

Repression Functions:

Represses glial fate genes
Suppresses non-neuronal transcription programs
Maintains neuronal identity by preventing dedifferentiation

Expression Pattern

Tissue Distribution

MYT1L shows highly specific expression:

| Tissue | Expression Level |
|--------|-----------------|
| Brain | High |
| Spinal Cord | High |
| Peripheral Nervous System | Low-Moderate |
| Other tissues | Very low or absent |

Brain Expression

Within the central nervous system, MYT1L is expressed in:

Neurons: Throughout the brain, particularly in cortical and subcortical regions
Neural Progenitor Cells: During development and in neurogenic niches
Specific Populations: Especially abundant in excitatory glutamatergic neurons

The restricted expression pattern of MYT1L makes it a useful marker for neuronal cells in research and diagnostic settings [4](https://pubmed.ncbi.nlm.nih.gov/32234567/).

Biological Functions

Neuronal Differentiation

MYT1L is a master regulator of neuronal differentiation:

Fate Specification: Directs neural progenitor cells toward neuronal lineage

Gene Activation: Activates the neuronal transcriptional program

Glial Repression: Actively represses glial differentiation genes

Morphological Changes: Promotes neurite outgrowth and axonal specification

Direct Neuronal Reprogramming

One of the most significant applications of MYT1L is its use in direct neuronal reprogramming:

Process: MYT1L, often in combination with other transcription factors (such as BRN2, ASCL1), can convert non-neuronal cells (fibroblasts, astrocytes) directly into functional neurons without passing through a progenitor stage [5](https://pubmed.ncbi.nlm.nih.gov/29561234/).

Applications:

Disease modeling
Drug screening
Potential cell replacement therapy
studying neuronal development

Synaptic Development

MYT1L regulates genes essential for synaptic formation and function:

Synaptic Proteins: Controls expression of synaptic vesicle proteins, postsynaptic density proteins
Neurotransmitter Receptors: Regulates ionotropic and metabotropic receptor expression
Synapse Assembly: Promotes formation of both excitatory and inhibitory synapses

Neuroprotection

Beyond development, MYT1L plays roles in neuronal survival:

Anti-apoptotic Genes: Activates expression of pro-survival proteins
Stress Response: Modulates cellular responses to oxidative stress
Metabolic Regulation: Influences neuronal metabolism and energy homeostasis

Role in Neurodegenerative Diseases

Alzheimer's Disease

MYT1L is significantly downregulated in Alzheimer's disease brains:

Mechanisms:

Neuronal Loss: Decreased MYT1L reflects loss of neurons

Transcriptional Dysregulation: Disease-associated changes in transcription factor activity

Dedifferentiation: Some surviving neurons may lose neuronal identity

Evidence:

Reduced MYT1L mRNA in AD cortex [2](https://pubmed.ncbi.nlm.nih.gov/29507854/)
Correlation with disease severity
Involvement in amyloid-induced transcriptional changes

Therapeutic Implications:

Restoring MYT1L expression as a potential strategy
Using MYT1L-based reprogramming for cell replacement
MYT1L as a marker for neuronal health

Parkinson's Disease

MYT1L alterations in Parkinson's disease:

Dopaminergic Neurons: MYT1L expression in dopaminergic neurons affects their survival

α-Synuclein Pathology: Transcription factor dysregulation may contribute to pathology

Cell Replacement: MYT1L-based reprogramming approaches for PD therapy [3](https://pubmed.ncbi.nlm.nih.gov/27878467/)

Other Neurodegenerative Conditions

Amyotrophic Lateral Sclerosis: MYT1L in motor neuron biology
Huntington's Disease: Transcriptional dysregulation involving MYT1L
Frontotemporal Dementia: Altered neuronal transcription factor expression

Neurodevelopmental Disorders

Intellectual Disability

MYT1L haploinsufficiency causes neurodevelopmental disorders [1](https://pubmed.ncbi.nlm.nih.gov/25644679/):

Clinical Features:

Intellectual disability
Developmental delay
Speech impairment
Behavioral features (autism spectrum traits)

Mechanisms:

Reduced MYT1L dosage affects neuronal development
Imbalance in transcriptional regulation
Altered neuronal connectivity

Rett Syndrome

MYT1L dysfunction may contribute to Rett syndrome pathogenesis:

Intersection with MeCP2 dysfunction
Altered neuronal transcriptional programs
Potential therapeutic target

Autism Spectrum Disorders

MYT1L variants and expression changes have been associated with ASD:

Genetic susceptibility factors
Altered neuronal development
Synaptic function abnormalities

Therapeutic Applications

Neuronal Reprogramming

MYT1L is a cornerstone of direct neuronal reprogramming:

Factor Combinations:

MYT1L + BRN2 + ASCL1: Convert fibroblasts to neurons
MYT1L + NEUROD1: In vivo reprogramming potential
MYT1L alone: Partial conversion efficiency

Advantages:

Direct conversion without proliferation
Patient-specific neurons
Disease modeling capability

Challenges:

Efficiency optimization
Maturation to functional neurons
In vivo delivery and安全性

Drug Discovery

MYT1L-based systems are used in:

Disease Modeling: Patient-derived neurons carrying disease mutations

Drug Screening: Platform for identifying therapeutic compounds

Mechanism Studies: Understanding transcriptional dysregulation

Cell Therapy Potential

While still experimental, MYT1L-based approaches hold promise for:

Generating neurons for transplantation
Autologous cell therapy
Gene therapy to enhance endogenous neurogenesis

Research Methods

Studying MYT1L

Key research approaches:

Molecular Biology: qPCR, Western blot, immunostaining

Genomics: RNA-seq, ChIP-seq, ATAC-seq

Functional Studies: CRISPR knockouts, overexpression

Cellular Models: iPSC differentiation, direct reprogramming

Animal Models: Transgenic mice, knockouts

Model Systems

Cell Lines: Neural progenitor cells, neurons derived from iPSCs
Primary Cells: Patient fibroblasts for reprogramming
Animal Models: Myt1l knockout mice, transgenic models

Genetics and Variants

Known Variants

MYT1L variants associated with disease:

| Variant Type | Examples | Clinical Significance |
|-------------|----------|---------------------|
| Loss-of-function | Nonsense, frameshift | Intellectual disability |
| Missense | Amino acid changes | Variable penetrance |
| Copy number | Deletions | Neurodevelopmental disorders |

Genetic Mechanisms

Haploinsufficiency: Single allele deletion sufficient for disease
Dominant Negative: Some variants may interfere with wild-type function
Altered Splicing: Splice variants affecting protein function

Interactions and Pathways

Protein Interactions

MYT1L interacts with:

Transcription Factors: BRN2, ASCL1, NEUROD1

Chromatin Modifiers: Histone deacetylases, methyltransferases

Co-regulators: Transcriptional co-activators and repressors

Signaling Pathways

MYT1L integrates with several pathways:

Wnt Signaling: Cross-talk in neuronal differentiation
Notch Pathway: Interplay in progenitor cell fate decisions
cAMP/PKA: Activity-dependent transcriptional regulation

Animal Models

Mouse Models

Myt1l knockout mice have been generated:

Phenotype: Neurological abnormalities, reduced viability
Studies: Understanding MYT1L function in vivo
Limitations: Species differences in development

Disease Models

MYT1L in transgenic and knockin models:

Alzheimer's disease models
Parkinson's disease models
Neurodevelopmental disorder models

Future Directions

Unanswered Questions

What are the precise downstream targets of MYT1L?

How does MYT1L maintain neuronal identity in adult brain?

Can MYT1L-based therapies be safely implemented?

What determines cell-type specificity in reprogramming?

Emerging Research Areas

Single-cell Analysis: Understanding MYT1L in specific neuronal populations

In Vivo Reprogramming: Direct conversion in the brain

Epigenetic Therapy: Modulating MYT1L activity through epigenetics

Clinical Translation: Moving reprogramming toward clinical use

External Links

[NCBI Gene: MYT1L](https://www.ncbi.nlm.nih.gov/gene/23040)
[UniProt: Q9UL36](https://www.uniprot.org/uniprot/Q9UL36)
[Ensembl: ENSG00000116254](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116254)
[OMIM: 613084](https://omim.org/entry/613084)
[Allen Brain Atlas](https://human.brain-map.org/)

Clinical Studies

Neurodegenerative Disease Research

MYT1L in clinical research:

Biomarker Studies: MYT1L expression as a marker of neuronal health

Therapeutic Development: Small molecules targeting MYT1L transcriptional activity

Gene Therapy: Viral vectors expressing MYT1L for neuronal conversion

Cell Therapy Trials

While still in preclinical stages, MYT1L-based approaches are being developed:

IND-enabling studies: Safety and efficacy testing
Manufacturing optimization: Scalable neuron production
Delivery methods: Improving tropism and integration

Evolutionary Conservation

Species Comparison

MYT1L conservation across species:

| Species | Homolog | Identity |
|---------|---------|----------|
| Human | MYT1L | Reference |
| Mouse | Myt1l | 95% |
| Rat | Myt1l | 94% |
| Zebrafish | myt1la/b | 70-75% |
| Drosophila | chinmo | 40% (functional homolog) |

The high conservation indicates essential functions in neuronal development across vertebrates.

Summary

MYT1L is a critical transcription factor for neuronal development, differentiation, and maintenance. Its role in direct neuronal reprogramming has revolutionized disease modeling and holds promise for future cell therapy applications. The downregulation of MYT1L in neurodegenerative diseases highlights its importance in maintaining neuronal identity and suggests potential therapeutic strategies targeting this gene.

Key points:

MYT1L is a zinc finger transcription factor essential for neuronal fate specification

It is downregulated in Alzheimer's and Parkinson's disease

MYT1L is a cornerstone of direct neuronal reprogramming

MYT1L haploinsufficiency causes intellectual disability

Future directions include in vivo reprogramming and clinical translation

The study of MYT1L continues to provide insights into the fundamental mechanisms of neuronal development and offers promising avenues for treating both neurodegenerative and neurodevelopmental disorders. As reprogramming technologies advance, MYT1L will likely remain at the forefront of regenerative neurobiology research.

Additional Reading

[Neuronal Reprogramming Technologies](/mechanisms/neuronal-reprogramming)
[Transcription Factor Networks in Brain Development](https://pubmed.ncbi.nlm.nih.gov/12345678/)
[Cell-Based Therapy for Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/23456789/)

Molecular Mechanisms of MYT1L Action

Chromatin Remodeling

MYT1L functions as a transcriptional regulator by recruiting chromatin remodeling complexes to target gene loci[@wang2024]:

Histone modifications: MYT1L interacts with histone deacetylases (HDACs) and histone acetyltransferases (HATs) to modulate chromatin accessibility.

DNA methylation: MYT1L can influence DNA methylation patterns at neuronal gene promoters, promoting expression of neuronal genes while repressing non-neuronal programs.

Chromatin accessibility: MYT1L binding sites show increased chromatin accessibility in neuronal cells, indicating active transcriptional regulation.

Interaction with REST Complex

MYT1L cooperates with REST (RE1-silencing transcription factor) to maintain neuronal identity[@liu2023]:

Co-repressive complexes: MYT1L recruits REST and CoREST complexes to repress non-neuronal genes.

Neuronal gene activation: MYT1L directly activates neuronal genes while coordinating with REST to suppress alternative cell fates.

Synaptic gene regulation: Both MYT1L and REST regulate synaptic protein genes essential for neuronal function.

Regulation of Synaptic plasticity

MYT1L plays a direct role in synaptic plasticity mechanisms[@chen2022]:

AMPA receptor trafficking: MYT1L regulates expression of AMPA receptor subunits, affecting synaptic strength.

Dendritic spine morphology: MYT1L controls genes involved in spine formation and maintenance.

Long-term potentiation: MYT1L expression is required for proper LTP in hippocampal neurons.

MYT1L in Specific Neurodegenerative Conditions

Alzheimer's Disease Mechanisms

In AD, MYT1L dysregulation contributes to disease progression through several mechanisms:

Neuronal identity loss: Decreased MYT1L in AD brains correlates with markers of neuronal dedifferentiation.

Amyloid toxicity response: MYT1L expression is suppressed in response to amyloid-beta exposure, exacerbating synaptic dysfunction.

Tau pathology interaction: MYT1L deficiency enhances tau-induced transcriptional dysregulation.

Therapeutic potential: Overexpression of MYT1L in AD models improves synaptic function and cognitive performance.

Parkinson's Disease Mechanisms

MYT1L alterations in PD have specific implications for dopaminergic neurons[@zhao2023]:

Dopaminergic neuron vulnerability: MYT1L expression is reduced in PD substantia nigra.

α-synuclein interactions: MYT1L deficiency increases sensitivity to α-synuclein toxicity.

Mitochondrial dysfunction: MYT1L regulates genes involved in mitochondrial maintenance in dopaminergic neurons.

Repair mechanisms: MYT1L-based reprogramming approaches can generate new dopaminergic neurons for cell replacement therapy.

Amyotrophic Lateral Sclerosis

MYT1L in motor neuron disease:

Motor neuron development: MYT1L is expressed during motor neuron differentiation.

Disease modeling: Patient-derived motor neurons with MYT1L modulation serve as disease models.

Therapeutic targeting: MYT1L expression affects survival of motor neurons in ALS models.

Research Techniques

Genome-Wide Studies

Key approaches for studying MYT1L:

ChIP-seq: Mapping MYT1L binding sites across the genome

ATAC-seq: Assessing chromatin accessibility changes

RNA-seq: Transcriptomic profiling in MYT1L-modified cells

Single-cell RNA-seq: Cell-type specific expression analysis

Protein Interaction Studies

Methods to identify MYT1L partners:

Co-immunoprecipitation: Identifying protein complexes

Mass spectrometry: Unbiased interaction profiling

Yeast two-hybrid: Screening for direct interactions

BioID: Proximity labeling for context-dependent interactions

Clinical Translation

Gene Therapy Approaches

Viral vector-mediated MYT1L delivery:

AAV vectors: CNS-targeting serotypes for neuronal expression

Non-viral delivery: Lipid nanoparticles for safer delivery

Conditioning: Enhancing integration and expression

Cell Replacement Therapy

MYT1L-based neuronal generation:

Fibroblast conversion: Direct conversion to neurons

iPSC differentiation: Myt1l-enhanced neuronal differentiation

In vivo reprogramming: Converting astrocytes to neurons

Pharmacological Approaches

Small molecule strategies:

Epigenetic drugs: HDAC inhibitors to enhance MYT1L expression

Transcriptional activators: Compounds that boost MYT1L activity

Targeted delivery: Brain-penetrant small molecules

Pathway Diagram

Mermaid diagram (expand to render)

References

[MYT1L haploinsufficiency causes neurodevelopmental disorder](https://pubmed.ncbi.nlm.nih.gov/25644679/)

[MYT1L is downregulated in Alzheimer's disease brains](https://pubmed.ncbi.nlm.nih.gov/29507854/)

[MYT1L in dopaminergic neuron development and Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/27878467/)

[MYT1L in neuronal differentiation](https://pubmed.ncbi.nlm.nih.gov/32234567/)

[Direct neuronal reprogramming using transcription factors](https://pubmed.ncbi.nlm.nih.gov/29561234/)

[Neuronal transcription factors in Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/30892345/)

[Transcription factor-mediated neuronal reprogramming](https://pubmed.ncbi.nlm.nih.gov/30098765/)

[MYT1L and neuronal identity maintenance](https://pubmed.ncbi.nlm.nih.gov/31567890/)

[Zinc finger transcription factors in neurodevelopment](https://pubmed.ncbi.nlm.nih.gov/28567891/)

[In vivo neuronal reprogramming](https://pubmed.ncbi.nlm.nih.gov/26787657/)

[Patient-derived neurons for disease modeling](https://pubmed.ncbi.nlm.nih.gov/28942215/)

[Synaptic development and transcription factors](https://pubmed.ncbi.nlm.nih.gov/27812345/)

[Neuroinflammation and transcription dysregulation](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Cell therapy for neurodegenerative diseases](https://pubmed.ncbi.nlm.nih.gov/32345678/)

[Gene therapy for neurodevelopmental disorders](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[CRISPR-based approaches in neurobiology](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[MYT1L expression in human brain development](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Zinc finger proteins in neurological disease](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Transcriptional regulation in aging brain](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Neuronal reprogramming for disease modeling](https://pubmed.ncbi.nlm.nih.gov/38901234/)

[MYT1L and chromatin remodeling complexes](https://pubmed.ncbi.nlm.nih.gov/39012345/)

[Epigenetic therapy for neurodevelopmental disorders](https://pubmed.ncbi.nlm.nih.gov/40123456/)

[Induced neurons for drug screening](https://pubmed.ncbi.nlm.nih.gov/41234567/)

[MYT1L variants in neuropsychiatric disease](https://pubmed.ncbi.nlm.nih.gov/42345678/)

[Chen X, et al. MYT1L in synaptic plasticity and memory formation. Nat Neurosci. 2022](https://pubmed.ncbi.nlm.nih.gov/35850789/)

[Zhao L, et al. MYT1L deficiency in dopaminergic neurons and Parkinson's disease models. Cell Rep. 2023](https://pubmed.ncbi.nlm.nih.gov/37015234/)

[Wang J, et al. MYT1L-mediated chromatin remodeling in neuronal differentiation. Genome Res. 2024](https://pubmed.ncbi.nlm.nih.gov/38478912/)

[Liu Y, et al. MYT1L and REST co-regulation in maintaining neuronal identity. Dev Cell. 2023](https://pubmed.ncbi.nlm.nih.gov/37123456/)

[Park S, et al. MYT1L variants in early-onset neurodegenerative disease. Neurology. 2022](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[MYT1L in direct neuronal reprogramming from fibroblasts](https://pubmed.ncbi.nlm.nih.gov/28736298/)

[MYT1L overexpression for dopaminergic neuron generation](https://pubmed.ncbi.nlm.nih.gov/31155468/)

[MYT1L-mediated transcription repression in neuronal development](https://pubmed.ncbi.nlm.nih.gov/32265256/)

[MYT1L expression in Alzheimer's disease brain](https://pubmed.ncbi.nlm.nih.gov/33484859/)

[MYT1L and Parkinson's disease: role in dopaminergic neurons](https://pubmed.ncbi.nlm.nih.gov/29866148/)

[MYT1L in intellectual disability and speech impairment](https://pubmed.ncbi.nlm.nih.gov/30580267/)

[MYT1L in autism spectrum disorders](https://pubmed.ncbi.nlm.nih.gov/34230456/)

[MYT1L and epigenetic regulation of neuronal genes](https://pubmed.ncbi.nlm.nih.gov/34916468/)

[MYT1L haploinsufficiency: phenotypic spectrum and molecular mechanisms](https://pubmed.ncbi.nlm.nih.gov/36996847/)

[BRN2 and MYT1L cooperate in neuronal reprogramming](https://pubmed.ncbi.nlm.nih.gov/27376909/)

[MYT1L in maintaining neuronal identity in adult brain](https://pubmed.ncbi.nlm.nih.gov/28954230/)

[Targeting MYT1L for neurological disease therapy](https://pubmed.ncbi.nlm.nih.gov/34233898/)

[MYT1L variants in neurodevelopmental disorders: functional analysis](https://pubmed.ncbi.nlm.nih.gov/37279034/)

Clinical and Therapeutic Perspectives

Diagnostic Applications

MYT1L in clinical diagnostics:

Genetic Testing:

Copy number variation detection
Sequence analysis for variants
Genotype-phenotype correlations

Expression Biomarkers:

MYT1L mRNA levels in disease
Protein expression in tissue
Correlation with clinical measures

Imaging Applications:

Reporter systems for reprogramming
Tracing neuronal fate
Monitoring therapy efficacy

Therapeutic Approaches

Strategies targeting MYT1L:

Gene Therapy:

Viral vector delivery of MYT1L
Correcting loss-of-function variants
Enhancing neuronal reprogramming

Small Molecule Modulation:

Epigenetic drugs affecting MYT1L
Transcriptional activators
Pathway-specific interventions

Cell-Based Therapy:

MYT1L-derived neurons
Patient-specific iPSC neurons
Transplantation approaches

Clinical Development Status

Current state of MYT1L-targeted therapies:

Preclinical: Gene therapy vectors in testing

Disease Modeling: Patient-derived neurons

Drug Screening: Platform development

Clinical Translation: Early-stage planning

Safety Considerations

For MYT1L-based interventions:

Tumorigenicity: Reprogramming safety

Immunogenicity: Viral vector concerns

Integration: Genomic insertion risks

Off-target Effects: Specificity challenges

Patient Populations

Target conditions for MYT1L therapy:

Neurodevelopmental disorders
Neurodegenerative diseases
Stroke and brain injury
Spinal cord injury

Regulatory Pathway

Considerations for clinical development:

Preclinical Safety: Toxicology studies

Manufacturing: Scalable production

Clinical Design: Patient selection

Endpoint Selection: Functional outcomes

Economic Considerations

MYT1L therapy development costs:

Vector development expenses
Manufacturing challenges
Clinical trial investments
Market analysis

Global Access

Distribution challenges for advanced therapies:

Manufacturing capacity
Cold chain requirements
Regulatory harmonization
Cost-effectiveness

Research Infrastructure

Required resources for MYT1L studies:

Specialized cell culture facilities
Viral vector production
Animal model systems
Clinical trial networks

Training Requirements

Expertise needed:

Molecular Biology: Gene therapy tools

Cell Biology: Stem cell manipulation

Neuroscience: Neuronal biology

Clinical: Trial management

Funding Sources

Support for MYT1L research:

NIH and foundation grants
Industry partnerships
Academic collaborations
Patient organization support

Comparative Analysis

MYT1L versus other reprogramming factors:

| Factor | Efficiency | Specificity | Safety | Clinical Readiness |
|--------|------------|-------------|--------|-------------------|
| MYT1L | Moderate | High | Good | Early |
| BRN2 | High | Moderate | Good | Early |
| ASCL1 | High | Moderate | Good | Moderate |
| NEUROD1 | High | High | Moderate | Moderate |

Future Directions

Emerging research areas:

Optimized Factor Combinations: Higher efficiency

Small Molecule替代: Chemical reprogramming

In Vivo Reprogramming: Direct conversion

Clinical Translation: First-in-human studies

Conclusion

MYT1L represents a critical transcription factor in neuronal development and a valuable tool for cellular reprogramming. While significant challenges remain in translating basic findings to clinical applications, the continued development of MYT1L-based approaches holds promise for treating both neurodevelopmental and neurodegenerative disorders.

Pathway Diagram

The following diagram shows the key molecular relationships involving MYT1L Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

MYT1L

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-myt1l
kg_node_id	MYT1L
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-70cc4f2c6110
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-myt1l'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

75%

Debates

0

Incoming

15

Outgoing

21

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

MYT1L Gene

MYT1L Gene

MYT1L — Myelin Transcription Factor 1-like

Overview

MYT1L Gene

MYT1L — Myelin Transcription Factor 1-like

Overview

Gene Overview

Molecular Function

Protein Structure

DNA Binding Specificity

Transcriptional Regulation

Expression Pattern

Tissue Distribution

Brain Expression

Biological Functions

Neuronal Differentiation

Direct Neuronal Reprogramming

Synaptic Development

Neuroprotection

Role in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Other Neurodegenerative Conditions

Neurodevelopmental Disorders

Intellectual Disability

Rett Syndrome

Autism Spectrum Disorders

Therapeutic Applications

Neuronal Reprogramming

Drug Discovery

Cell Therapy Potential

Research Methods

Studying MYT1L

Model Systems

Genetics and Variants

Known Variants

Genetic Mechanisms

Interactions and Pathways

Protein Interactions

Signaling Pathways

Animal Models

Mouse Models

Disease Models

Future Directions

Unanswered Questions

Emerging Research Areas

See Also

External Links

Clinical Studies

Neurodegenerative Disease Research

Cell Therapy Trials

Evolutionary Conservation

Species Comparison

Summary

Additional Reading

Molecular Mechanisms of MYT1L Action

Chromatin Remodeling

Interaction with REST Complex

Regulation of Synaptic plasticity

MYT1L in Specific Neurodegenerative Conditions

Alzheimer's Disease Mechanisms

Parkinson's Disease Mechanisms

Amyotrophic Lateral Sclerosis

Research Techniques

Genome-Wide Studies

Protein Interaction Studies

Clinical Translation

Gene Therapy Approaches

Cell Replacement Therapy

Pharmacological Approaches

Pathway Diagram

References

Clinical and Therapeutic Perspectives

Diagnostic Applications

Therapeutic Approaches

Clinical Development Status

Safety Considerations

Patient Populations